

Hansa Medical

- PRESS RELEASE -
June 7, 2017

Hansa Medical to present at Jefferies 2017 Global Healthcare Conference

Hansa Medical will present at the Jefferies 2017 Global Healthcare Conference on June 9 in New York City. Göran Arvidson, Chief Executive Officer, will present at the conference at 1:00 p.m. EDT. (7:00 p.m. CEST).

A live audio webcast of the presentation will be accessible through the Hansa Medical website www.hansamedical.com and through the following link:
<http://wsw.com/webcast/jeff105/hmed>

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.

The information was submitted for publication, through the agency of the contact person set out below, at 8 am CEST on June 7, 2017.

For further information, please contact:

Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobile: +46707175477
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com

Cord Communications, Stockholm
Mikael Widell
Mobile: +46 70 311 9960

Lars Wahlström
Mobile: +46 73 434 0771

FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000